http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2707265-C1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f1d939c0d98d930384292e9581806d33
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B3-10
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B3-10
filingDate 2018-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2019-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_47cb81906e72c33f436e8e0baf315f1d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ee7cadfbe918fd12a20d6c355d9c181
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac14df56b8b1cb7741e1521b8beb7006
publicationDate 2019-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber RU-2707265-C1
titleOfInvention Method for determining the boundaries of full-thickness eyelid resection in malignant growths of epithelial genesis
abstract FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to ophthalmology, and can be used for determining borders of full-length eyelid resection in malignant growths of epithelial genesis. During non-contact infrared mebography, the meibomian gland "fallout" area is determined in a conjunctival tumor projection. If the nodular, nodular-ulcerous and ulcerous forms of basal cell carcinoma are localized in the middle one-third of the eyelid, the resection limits are determined by vertical lines drawn through a third unmodified meibomia gland on either side of the meibomian glands prolapse. If localization in the medial or lateral third of the eyelid is concerned, the resection limits are determined on a vertical line drawn through a third unmodified meibomia gland on one side and on a visual border of tumor at 3 mm from the other. In squamous cell scleroderm-like form of basal cell carcinoma with the tumor in the middle third of the eyelid, the resection limits are determined by vertical lines drawn through the fifth unmodified meibomia gland on each side of the "prolapse" zone. When localising in the medial or lateral third of the eyelid, the resection limits are determined on a vertical line through the fifth unmodified meibomia gland on one side and on the visual border of the tumor with indent of 4–5 mm on the other side.EFFECT: method provides accurate determination of eyelid resection limits for radical removal of a new growth at a preoperative stage with resection of an abdominal cavity and reducing the recurrence rate by determining the borders of the eyelid neoplasm based on the recording of the meibomian gland absent ("falling out") region during noncontact infrared mebography with obtaining images of the high-definition eyelid meibomian glands.1 cl, 4 ex
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114913124-A
priorityDate 2018-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2007118199-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2500340-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2373832-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8249695-B2
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID86598188
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID450235101

Total number of triples: 21.